Literature DB >> 2344160

In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

G S Kobayashi1, S J Travis, M G Rinaldi, G Medoff.   

Abstract

The antifungal activities of amphotericin B and two triazoles, Sch 39304 and fluconazole, were tested against Histoplasma capsulatum. In this study Sch 39304 compared favorably with amphotericin B in treating histoplasmosis in normal and leukopenic mice, whereas fluconazole was much less active. The differences in the efficacies of the triazoles appeared to be due to differences in their pharmacokinetics and the dosage schedule that was used. For amphotericin B there was a good correlation between in vitro and in vivo efficacy, but this was not true of the triazole derivatives. These results further demonstrate that, with the methods used in this study, in vitro susceptibility testing of triazoles may not be predictive of in vivo activity against isolates of H. capsulatum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2344160      PMCID: PMC171637          DOI: 10.1128/AAC.34.4.524

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Cryptococcal meningitis and fluconazole.

Authors:  B Dupont; E Drouhet
Journal:  Ann Intern Med       Date:  1987-05       Impact factor: 25.391

Review 2.  Antifungal susceptibility tests.

Authors:  J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

3.  In vitro and in vivo comparisons of amphotericin B and N-D-ornithyl amphotericin B methyl ester.

Authors:  G S Kobayashi; J R Little; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

4.  Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice.

Authors:  P F Troke; R J Andrews; M S Marriott; K Richardson
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

5.  Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis.

Authors:  D V Savani; J R Perfect; L M Cobo; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

6.  Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice.

Authors:  G S Kobayashi; S J Travis; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

7.  Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans.

Authors:  C E Hughes; R L Bennett; I C Tuna; W H Beggs
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

Review 8.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

9.  Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.

Authors:  K Richardson; K W Brammer; M S Marriott; P F Troke
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

10.  Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

View more
  9 in total

Review 1.  Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

Authors:  K N Sorensen; K V Clemons; D A Stevens
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

2.  Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice.

Authors:  A Cacciapuoti; D Loebenberg; R Parmegiani; B Antonacci; C Norris; E L Moss; F Menzel; T Yarosh-Tomaine; R S Hare; G H Miller
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice.

Authors:  P Connolly; L J Wheat; C Schnizlein-Bick; M Durkin; S Kohler; M Smedema; J Goldberg; E Brizendine; D Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  In vitro antifungal susceptibility profile and correlation of mycelial and yeast forms of molecularly characterized Histoplasma capsulatum strains from India.

Authors:  Shallu Kathuria; Pradeep K Singh; Jacques F Meis; Anuradha Chowdhary
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

5.  Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

6.  In vitro and in vivo activities of SCH 42427, the active enantiomer of the antifungal agent SCH 39304.

Authors:  D Loebenberg; A Cacciapuoti; R Parmegiani; E L Moss; F Menzel; B Antonacci; C Norris; T Yarosh-Tomaine; R S Hare; G H Miller
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

7.  Interactions of amphotericin B and SCH 39304 in the treatment of experimental murine candidiasis: lack of antagonism of a polyene-azole combination.

Authors:  A M Sugar
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

8.  Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.

Authors:  P Connolly; J Wheat; C Schnizlein-Bick; M Durkin; S Kohler; M Smedema; J Goldberg; E Brizendine; D Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

9.  In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.

Authors:  Toru Nakai; Jun Uno; Fumiaki Ikeda; Shuichi Tawara; Kazuko Nishimura; Makoto Miyaji
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.